by The estrogen blockers market consists of pharmaceutical drugs that are used to treat breast cancer, prostate cancer, and other hormone-sensitive conditions by blocking the effects of the hormone estrogen in the body. Estrogen blockers, also known as antiestrogens, work by blocking estrogen receptors on breast or other cells, preventing estrogen from binding and stimulating the growth of cancerous or precancerous tumors.
The global Estrogen Blockers Market is estimated to be valued at US$ 15.02 Billion in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing awareness about the benefits of estrogen blockers in treating various types of cancers and hormone-sensitive conditions has been a key trend propelling the growth of the estrogen blockers market. Various government initiatives and programs focused on cancer awareness as well as education initiatives by leading pharmaceutical companies regarding newer anti-cancer therapies have substantially increased awareness about estrogen blockers as an important medication for the treatment of hormone receptor-positive breast cancer and other estrogen-dependent cancers. This has resulted in rising demand for estrogen blockers globally. Additionally, increasing investment in research and development of novel and more effective estrogen blocker drugs also supports the market growth.
SWOT Analysis
Strength: Estrogen blockers provide an effective treatment for hormonally driven cancers such as breast cancer and ovarian cancer. They help block the effects of estrogen in the body.
Weakness: Estrogen blockers may cause side effects like hot flashes, loss of bone density, mood changes and weight gain. They do not work for all types of cancers and may lose effectiveness over time for some patients.
Opportunity: Growing aging population, increasing awareness about hormonal cancers and expanding indications offer lucrative opportunities for market players. Demand is growing for improved formulations with reduced side effects.
Threats: Patent expiries of blockbuster drugs result in decline of revenues for companies. Limited R&D pipelines for developing next generation molecules pose threats. Intense competition affects pricing of drugs.
Key Takeaways
Global Estrogen Blockers Market Size is expected to witness high growth. With rising prevalence of hormone-driven cancers, the demand for drugs inhibiting the effects of estrogen is increasing steadily. The market valued at US$ 15.02 Billion in 2023 is projected to reach US$ 19.13 Bn by 2030, expanding at a CAGR of 5.9% during the forecast period.
Regional analysis comprises North America dominates the market currently owing to growing diagnosis and treatment rates of breast cancer in the US and Canada. Asia Pacific is emerging as a fast growing regional market with improving healthcare facilities in countries like China, India and Japan. Japan holds the largest share in the Asia Pacific estrogen blockers market.
Key players:
Key players operating in the Estrogen Blockers market are Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mylan N.V., Aurobindo Pharma USA Inc., Glenmark Pharmaceuticals Inc., USA., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals USA Inc. Teva Pharmaceutical Industries Ltd. currently leads the market with over 30% share driven by its generic versions of tamoxifen therapy.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
